GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (FRA:PHGN) » Definitions » Policyholder Funds

Pharming Group (FRA:PHGN) Policyholder Funds


View and export this data going back to . Start your Free Trial

What is Pharming Group Policyholder Funds?

Policyholder Funds only applies to insurance companies.


Pharming Group Business Description

Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.